Neural and Immune Correlates of Painful Chemotherapy-Induced Neuropathy, Feasibility and Preliminary Efficacy of a Motor Cortex Non-Invasive Brain Stimulation Intervention

Over half of cancer patients receiving common chemotherapy treatments experience painful nerve damage called chemotherapy-induced peripheral neuropathy (CIPN). Non-Hispanic Black (NHB) patients are more likely to suffer from this condition and more often need to reduce their chemotherapy doses compared to Non-Hispanic White (NHW) patients.
Currently, only one medication, duloxetine, is approved for treating CIPN, but it doesn't work for everyone. A new approach, transcranial direct current stimulation (tDCS), shows promise as a safe and effective treatment. tDCS can be done at home and reduces the need for hospital visits.
Research indicates that tDCS can improve pain responses in the brain's pain control network. There are differences in pain sensitivity and brain activity related to pain between NHB and NHW individuals, which may influence the effectiveness of treatments.
This research aims to conduct a study to:
1. Test if tDCS is a helpful treatment for painful CIPN.
2. Investigate how CIPN affects brain function in NHB and NHW patients.
3. Examine the role of inflammation in CIPN and its connection to pain severity and brain function.
The investigators expect that NHB patients will benefit more from tDCS due to differences in their brain's pain response system. This project aims to address health disparities and improve outcomes for urban communities, particularly in Baltimore.

Start Date01 Mar 2025

Sponsor / Collaborator

Morgan State University

[+1]

NCT06519487

/ RecruitingNot ApplicableIIT

Perceived Discrimination, Geography, and Demographic Effects on Immune Cell Function and Regulation

Immune-mediated inflammatory diseases are a health burden for approximately seven percent of the population of Western nations. Preliminary data suggest variations in ethnic identity and/or geography influence discrimination experiences and inflammatory response trends. This study investigates how geography, ethnicity, and laboratory manipulation of discrimination experiences affect immune cell function and genomic regulation. Flow cytometry and immune cell stimulation will test monocytes collected from peripheral blood for functional effects. Next-generation transcriptomics and epigenomics will assess genomic and epigenetic mechanisms. The hypothesis is that geography, self-identified race, and ethnicity, interacting with laboratory discrimination conditions during the virtual ballgame Cyberball™, significantly affect immune cell function through genomic and epigenetic mechanisms, with perceived discrimination as a moderating factor on the immune outcomes. The transdisciplinary nature of the proposed study aims to provide valuable insights into differential susceptibility to immune-mediated inflammatory diseases across diverse populations. Uncovering these insights will better inform population-relevant interventions for immune-mediated inflammatory diseases.

Start Date03 Feb 2025

Sponsor / Collaborator

Morgan State University

[+3]

NCT06633367

/ CompletedNot ApplicableIIT

Nature Dose Equity for Students

This project will first examine nature opportunities, belonging and benefits with a multi-state nature-based intervention with a focus on students of color. In light of the syndemic, 'nature deficit disorder' and poor mental health, the investigators anticipate several far-reaching impacts that will (a) test a nationally useful standardized way to quantify exposure; (b) invest in nature resources and accessibility on campuses; and (c) promote the mental health and therapeutic benefits of nature among young adults. These will lead to understanding the nature exposure and mental health interplay and techniques for quantifying and encouraging nature exposure to treat the on-going youth mental health crisis. Including HBCUs and an hispanic-serving institution is expected to result in heightened visibility of underlying disparities, including structural racism and land-based violence and discrimination, that have contributed to current-day nature gaps and dismantled nature relationships for students of color.

Start Date09 Sep 2024

Sponsor / Collaborator

Michigan State University

[+8]

100 Clinical Results associated with Morgan State University

0 Patents (Medical) associated with Morgan State University

1,315

Literatures (Medical) associated with Morgan State University

01 Dec 2025·COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

The role of AI for improved management of breast cancer: Enhanced diagnosis and health disparity mitigation

Review

Author: Gichoya, Judy Wawira ; Khalifa, Fahmi ; Akinniyi, Oluwatunmise ; Rahman, Md Mahmudur ; Weaks, Francesca ; Saleh, Gehad A ; Aina, Joseph ; Meeker, Timothy ; Trivedi, Hari ; Dixon, Jose

Breast Cancer (BC) remains a leading cause of morbidity and mortality among women globally, accounting for 30% of all new cancer cases (with approximately 44,000 women dying), according to recent American Cancer Society reports. Therefore, accurate BC screening, diagnosis, and classification are crucial for timely interventions and improved patient outcomes. The main goal of this paper is to provide a comprehensive review of the latest advancements in BC detection, focusing on diagnostic BC imaging, Artificial Intelligence (AI) driven analysis, and health disparity considerations. We first examine diverse imaging techniques such as Mammography, Ultrasound, and Dynamic Contrast-Enhanced Magnetic Resonance Imaging, and provide an overview of their pros and cons. Then, we provided an intensive review of the State-of-the-Art (SOTA) literature on the role of AI in BC classification and segmentation. Lastly, we examined the role of AI in BC health disparities. A key contribution of this work lies in its integrative approach, consolidating insights from multiple research areas, imaging methods, AI-driven methodologies, and health disparities in a single resource. This paper evaluates the effectiveness of modern AI-based tools in enhancing diagnostic accuracy and discusses their potential to address biases in BC diagnosis, thus promoting equitable healthcare access. By integrating clinical, technical, and equity perspectives, this review aims to inform real-world decision-making, supporting the development of bias-aware AI tools, guiding equitable screening policy, and enhancing clinical practice in breast cancer care. Additionally, our critical analysis and discussion of recent SOTA highlights the strengths, limitations, and knowledge gaps for future directions of AI roles in BC. In total, these findings and future venue suggestions serve as a practical reference for researchers, clinicians, and policymakers, underscoring the need for interdisciplinary collaboration to harness AI's full potential in BC diagnosis and reduce global health disparities.

01 Dec 2025·Drug and alcohol dependence reports

Opioid biomarkers in urine as reliable and valid correlates of opium use characteristics: A 10-year longitudinal assessment

Article

Author: Abnet, Christian C ; Poustchi, Hossein ; Malekzadeh, Reza ; Shaner, Rebecca L ; Naghash, Mahdokht ; Freedman, Neal D ; Boffetta, Paolo ; Tuachi, Abraham ; Kamangar, Farin ; Williams, Katrice D ; Etemadi, Arash ; Hamelin, Elizabeth I ; Roshandel, Gholamreza

Background:

Biomarkers can clarify the mechanistic bases of health effects associated with opiate use and improve evaluating dose-response relationships by quantifying the absorbed dose through different routes and patterns of use, supporting the generalizability of opium research findings to broader opioid use.

Methods:

We recruited 449 individuals who used opium and 66 individuals who did not, 10 years after baseline evaluation in a cohort study. At both time points, we collected self-reported characteristics of opium use (route, frequency, type, and dose) and measured urinary concentrations of codeine, hydrocodone, hydromorphone, morphine, morphine-3-glucuronide, and morphine-6-glucuronide in spot urine samples. We used multivariate linear regression models to determine the independent effects of each opium use characteristic on biomarker concentrations. Reliability of biomarker concentrations over the 10-year interval was assessed using intraclass correlation coefficients (ICCs) from linear mixed-effect models.

Results:

At the follow-up, 229 (51.0 %) subjects used opium by ingestion, which showed a significant shift compared with baseline (24.4 % ingestion). In adjusted models, opium ingestion, daily use, and presence of opioid use disorder (OUD) were associated with higher concentrations of all opioid biomarkers compared with opium smoking, non-daily use, and absence of OUD, respectively. All opioid biomarkers showed significant dose-response relationships relative to self-reported doses. Biomarker concentrations peaked when opium was used 3-4 h before sample collection and declined afterwards, remaining detectable for several days. Biomarker measurements were reliable (ICCs between 0.69 and 0.78) over the 10-year interval.

Conclusions:

Opioid biomarkers are valid markers of lifetime history, route, frequency, dose, and recency of opium use and OUD diagnosis, and demonstrate good long-term reliability.

01 Nov 2025·SCIENCE OF THE TOTAL ENVIRONMENT

From carboxylates to chlorinated sulfonates: Contrasting fate and treatment prospects of GenX and F 53B in WWTPs

Review

Author: Zhang, Huimin ; Sherchan, Samendra P

HFPO-DA (GenX) and Cl-PFAES (F53B) are structurally distinct PFAS that behave differently in wastewater treatment plants (WWTPs). GenX, with a fully fluorinated ether backbone and high polarity, shows low sorption and persists in the aqueous phase. In contrast, F-53B's sulfonate group and non-fluorinated segments favor sludge partitioning, with potential desorption risks. Mechanistically, the CCl substituent in F53B can act as a microbial dehalogenation hotspot that precedes defluorination, whereas GenX shows limited biotransformation. In mixed matrices, competitive sorption and precursor transformation decrease removal efficiency, with short-chain species most affected. Non-destructive methods, including advanced adsorbents, membranes, and anion-exchange resins, have demonstrated variable removal efficiencies (10-99 %). Destructive approaches such as UV/sulfite photoreduction and electrochemical oxidation show promise for partial degradation (70-99 %), although their practical application is constrained by matrix complexity, material specificity, and risks of secondary pollution. In addition, both compounds generate persistent transformation products, such as trifluoroacetic acid (TFA) from GenX and PFBS-like species from F53B, which raise additional environmental and regulatory concerns. Their molecular structures critically influence transformation behavior, with GenX resisting biodegradation due to its fluorinated ether backbone, and F53B showing greater reactivity owing to aliphatic -CH₂- groups and a chlorine substituent. Field-scale performance data and long-term monitoring remain limited, impeding accurate evaluation of treatment efficacy and environmental transformation. This review proposes a structure-fate-treatment framework and highlights the need for integrated byproduct monitoring, biotransformation research, and machine learning-assisted prediction to inform future remediation and policy efforts.

News (Medical) associated with Morgan State University

10 Nov 2025

·www.prnewswire.com

TEDCO's Maryland Innovation Initiative Announces Recent Company Formation and Technology Assessment Awardees

Maryland Innovation Initiative awards more than $2 million across 14 projects COLUMBIA, Md., Nov. 10, 2025 /PRNewswire/ -- TEDCO, Maryland's economic engine for technology companies, announced the next round of the Maryland Innovation Initiative (MII)'s Company Formation and Technology Assessment awardees, marking a significant milestone in promoting the commercialization of groundbreaking research from Maryland's prestigious academic research institutions. Continue Reading MII Awards stock image Dr. Abi Kulshrehstha, MII Executive Director Maryland Innovation Initiative (PRNewsfoto/TEDCO) "The MII remains dedicated to supporting the continued growth of our innovation ecosystem," said Abi Kulshreshtha, executive director, MII, TEDCO. "We are excited to see the MII's continued traction across the state. In these award cycles the MII staff and technical reviewers selected 14 awardees, eight for the Company Formation awards – totaling about $1.75 million – and six for the Technology Assessment awards – a total of around $780,000." The Company Formation award is provided to support the efforts to commercialize technology licensed from Qualifying Universities. The eight awardees for the January and April 2025 cycles include: Vascular Rescue Inc. - Advancing the development of automated vascular access 1104 Health, LLC - Accelerating access to oncology care options and improving health equity with the 1104Health Shared Care Platform SHARP Diagnostics, Inc. - SHARP Platform for enabling single-step molecular assays Droserix, LLC - Commercializing nanoscale electrodes for higher-resolution neurotransmitter detection Lithinity, LLC - LiON's Share: Commercializing MOF-polymer Membranes for direct extraction of lithium ions from brine Nodal Therapeutics Inc.- Re-educating the immune system with lymph node depots to induce safe and durable remission in celiac CurveAssure, Inc. - At-home neurological evaluation through scalable smartphone-based functional assessments NanoForge Systems Corp. - Handheld nitrate sensing platform The Technology Assessment award is a nine-month project that builds strong preliminary data that demonstrates the technology's utility for specific commercial applications beyond basic research. The six awardees for the April 2025 cycle include: Sujatha Kannan - Cell-targeted dendrimer-drug therapies for safe, convenient, and effective treatment of obesity and atherosclerosis Kevin Daniels - A universal rapid, ultrasensitive, and selective biological diagnostic and detection system based on epitaxial graphene Aryya Gangopadhyay - AI-enabled multi-sensor vest for real-time situational awareness in high-risk operations Ishan Barman - D-SENSE: Deep learning-powered digital SERS for rapid and ultrasensitive bioprocess monitoring Jose Ortiz - Automating language assessment: Enhancing DLD diagnosis for bilingual children Justin Hanes - Non-viral brain-penetrating gene therapy for effective treatment of Parkinson's Disease "MII is proud to bring innovation from lab to market," said Renée Winsky, chair of the MII Board of Directors. "Since inception, it has supported the creation of more than 450 jobs, created or supported more than 215 startups, and invested over $63 million in the Maryland innovation ecosystem; we look forward to continuing this progress." MII's Funding Opportunities The MII program, administered by TEDCO, was created as a collaboration between the State of Maryland and five leading academic research institutions—Johns Hopkins University, Morgan State University, University of Maryland, Baltimore, University of Maryland, Baltimore County and University of Maryland, College Park— that aims to leverage each institution's strengths to transition promising technologies into the commercial sector. "Across Maryland's universities, we can find researchers, innovators and even dreamers – it is essential that we continue providing avenues to these individuals as they support the state's economic development and innovation ecosystem," said TEDCO CEO Troy LeMaile-Stovall. "This is why we are so excited to see the continued traction the MII has received over the past 13 years and we hope to see the continued growth for years to come." MII has also expanded its reach to include comprehensive universities, along with the creation of the Baltimore Innovation Initiative (BII) with the goal of fostering a more equitable innovation and entrepreneurial ecosystem across Maryland. For more information, visit the MII webpage. About TEDCO TEDCO, the Maryland Technology Development Corporation, enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland. Learn more at . Media Contact Tammi Thomas, Chief Development & Marketing Officer, TEDCO, [email protected] Rachael Kalinyak, Associate Director, Marketing & Communications, TEDCO, [email protected] SOURCE TEDCO 21% more press release views with Request a Demo

24 Apr 2025

·www.prnewswire.com

TEDCO's Maryland Innovation Initiative Announces FY2025 Technology Assessment Awards

Over $1 million awarded to 7 university projects COLUMBIA, Md., April 24, 2025 /PRNewswire/ -- TEDCO, Maryland's economic engine for technology companies, announced the next round of Maryland Innovation Initiative (MII)'s Technology Assessment awards, marking a significant milestone in promoting the commercialization of groundbreaking research from Maryland's prestigious academic research institutions. The Technology Assessment award is a nine-month project that builds on strong preliminary data that demonstrates the technology's utility for specific commercial applications beyond basic research. TEDCO MII Team Maryland Innovation Initiative (PRNewsfoto/TEDCO) Over $1 million awarded to 7 university projects in Maryland Post this "The Technology Assessment phase of our program provides non-dilutive funding to advance technologies with commercial potential," said Abi Kulshreshtha, MII's executive director. "In this award cycle, the Maryland Innovation Initiative staff and technical reviewers selected seven projects from a competitive pool of applicants, which altogether received grants totaling more than $1 million to advance innovations ranging from new cancer therapeutics to inclusive AI-driven education technology solutions." The seven awardees are below: Heather Ames: Cell-HKer/siRaf, a promising therapeutic for Solid Tumors; University of Maryland, Baltimore Kevin Aroom: The Baby Gro Pro Smartscale: improving early diagnosis of medical problems and rare diseases; University of Maryland, College Park Steven Bernstein: Development of a novel optic nerve-stem cell therapy for glaucoma prevention and treatment; University of Maryland, Baltimore Won Jin Ho: Targeting PTPN22 for cancer immunotherapy; Johns Hopkins University Melanie Killen: Utilizing natural language processing technology for creating inclusive classrooms resubmission; University of Maryland, College Park Yuxing Li: Development and evaluation of a C. difficile-specific endolysin and dual therapy for C. difficile infection; University of Maryland, Baltimore Venkataramana Sidhaye: Development of a novel inhaled gene therapy, based on HAPLN1 transgene expression, for treating COPD; Johns Hopkins University Startup companies joining TEDCO's MII portfolio have access to a variety of TEDCO resources including mentor opportunities. A complete list of funded companies can be found on the MII webpage (here). MII's Funding Opportunities The MII program, administered by TEDCO, was created as a collaboration between the State of Maryland and five leading academic research institutions—Johns Hopkins University, Morgan State University, University of Maryland, Baltimore, University of Maryland, Baltimore County, and University of Maryland, College Park— that aims to leverage each institution's strengths to transition promising technologies into the commercial sector. "MII continues to bring innovation from lab to market," said Renée Winsky, chair of the MII Board of Directors. "Since inception, it has supported the creation of nearly 400 jobs, created or supported more than 190 startups, and invested over $58 million in the Maryland innovation ecosystem and we look forward to continuing this progress." MII has also expanded its reach to include two additional comprehensive universities, Frostburg State University and Bowie State University, along with the creation of the Baltimore Innovation Initiative (BII). All of these pilot programs aim to foster a more equitable innovation and entrepreneurial ecosystem across Maryland. For more information, visit the MII webpage. About TEDCO TEDCO, the Maryland Technology Development Corporation, enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland. Learn more at . Media Contact Tammi Thomas, Chief Development & Marketing Officer, TEDCO, [email protected] Rachael Kalinyak, Associate Director, Marketing & Communications, TEDCO, [email protected] SOURCE TEDCO WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Immunotherapy

31 Oct 2024

·www.prnewswire.com

Uwill Wins Best Mental Health Technology

Merit Awards recognize mental health leader with top honors in healthcare category for its impact on student mental health NATICK, Mass., Oct. 31, 2024 /PRNewswire/ -- Uwill, the leading mental health and wellness solution for colleges and students, was honored as the 2024 Merit Awards for Healthcare 'Gold' winner for 'Best Mental Health Technology'. "The 2024 Healthcare winners represent the absolute best in healthcare innovation," said Marie Zander, Executive Director of the Merit Awards. "These pioneers are setting a high bar for the future of healthcare, and we are honored to recognize their exceptional contributions." The Merit Awards Healthcare program honors organizations that have made significant contributions to healthcare across a range of categories. The winners were selected by a distinguished panel of industry experts for their remarkable achievements in improving healthcare delivery and innovation. "Our team is honored to receive this award, which underscores our commitment to offering immediate mental health and wellness support, eliminating all barriers to care," said Michael London, Founder and CEO of Uwill. "We're dedicated to meeting the mental health needs of all students. This award reflects the positive impact our technology and our counselor community have made on campuses nationwide." Utilizing its proprietary technology and counselor team, Uwill pioneered the first student and therapist matching platform. The solution offers an immediate appointment with a licensed counselor based on student preferences, all modalities of teletherapy, a direct crisis connection, wellness events, realtime data, and support. Uwill serves more than 3 million students from all 50 states at institutions including Rutgers University, the Alabama Community College System, Morgan State University, and University of California, Santa Barbara. About Uwill: Uwill is the leading mental health and wellness solution for colleges and students, and the 27th fastest growing private company in the nation. As the most cost-effective way to enhance a college's mental health offering, Uwill partners with more than 400 institutions, including Princeton University, the Ohio State University, Santa Fe Community College, and University of Alabama - Online. Uwill is also the exclusive teletherapy education partner for the Online Learning Consortium and teletherapy education partner of NASPA. For more information, visit uwill.com. Contact: Brett Silk [email protected] SOURCE Uwill, Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Morgan State University

100 Translational Medicine associated with Morgan State University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 11 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Current Projects

Drug(Targets)	Indications	Global Highest Phase

US20250346617 Patent Mining	Neoplasms More	Discovery

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis